Research progress of inflammatory myofibroblastic tumor in head and neck region

doi:10.19438/j.cjoms.2018.01.018

Abstract

Abstract: Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm, composed of myofibroblasts/ fibroblasts, plasma cells, lymphocytes and/or infiltrating eosinophils. It is not common in the head and neck region, which resulted in the lack of standards of treatment and prognosis for the disease. This paper reviewed the current literature on the etiology, clinical features, pathology, treatment and prognosis of IMT in order to facilitate better recognition and treatment of IMT in head and neck region.

Key words: Inflammatory myofibroblastic tumor, ALK, Cox-2 inhibitor

CLC Number:

R739.8

PENG Can-bang, TIAN Zhen, JI Tong. Research progress of inflammatory myofibroblastic tumor in head and neck region[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(1): 84-88.

References

[1] Al-Humidi A, Al-Khamiss A.Inflammatory myofibroblastic tumor arising in the external ear: unexpected location. (case report)[J]. Int J Health Sci (Qassim), 2015, 9(2): 201-205.
[2] Coffin CM, Humphrey PA, Dehner LP.Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey[J]. Semin Diagn Pathol, 1998, 15(2): 85-101.
[3] Gleason BC, Hornick JL.Inflammatory myofibroblastic tumors: where are we now?[J]. J Clin Pathol, 2008, 61(4): 428-437.
[4] Mariño-Enríquez A, Wang WL, Roy A, et al.Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK[J]. Am J Surg Pathol, 2011, 35(1): 135-144.
[5] Meis JM, Enzinger FM.Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor[J].Am J Surg Pathol, 1991, 15(12): 1146-1156.
[6] Coffin CM, Fletcher JA.Inflammatory myofibroblastic tumor.World Health Organization classification of tumors. WHO classification of soft tissue and bone [M]. 4th Ed. Lyon: IARc Press, 2013: 83-84.
[7] Tao J, Zhou ML, Zhou SH.Inflammatory myofibroblastic tumors of the head and neck[J]. Int J Clin Exp Med, 2015, 8(2): 1604-1610.
[8] Fletcher CDM, Unni KK, Mertens F.World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone [M]. Lyon: IARC Press, 2002: 91-93.
[9] Mehta B, Mascarenhas L, Zhou S, et al.Inflammatory myofibroblastic tumors in childhood[J]. Pediatr Hematol Oncol, 2013, 30(7): 640-645.
[10] Coffin CM, Dehner LP, Meis-Kindblom JM.Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: An historical review with differential diagnostic considerations[J]. Semin Diagn Pathol, 1998, 15(2): 102-110.
[11] Hytiroglou P, Brandwein Ms, Strauchen JA, et al.Inflammatory pseudotumor of the parapharyngeal space: case report and review of the literature[J]. Head Neck, 1992, 14(3): 230-234.
[12] Coffin CM, Patel A, Perkins S, et al.ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor[J]. Mod Pathol, 2001, 14(6): 569-576.
[13] Yamamoto H, Yoshida A, Taguchi K, et al.ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours[J]. Histopathology, 2016, 69(1): 72-83.
[14] Morris SW, Kirstein MN, Valentine MB.Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin' s lymphoma[J]. Science, 1994, 263(5151): 1281-1284.
[15] 孟宇宏, 吴惠. ALK与ALK阳性肿瘤的病理诊断与治疗进展[J]. 诊断病理学杂志, 2014, 21(6): 361-366.
[16] Lawrence B, Perez-Atayde A, Hibbard MK, et al.TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors[J]. Am J Pathol, 2000, 157(2): 377-384.
[17] Bridge JA, Kanamori M, Ma Z, et al.Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor[J]. Am J Pathol, 2001, 159(2): 411-415.
[18] Cools J, Wlodarska I, Somers R, et al.Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor[J]. Genes Chromosom Cancer, 2002, 34(4): 354-362.
[19] Chen ST, Lee JC.An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features[J]. Hum Pathol, 2008, 39(12): 1854-1858.
[20] Yamamoto H, Kohashi K, Oda Y, et al.Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene[J]. Pathol Int, 2006, 56(10): 584-590.
[21] Takeuchi K, Soda M, Togashi Y, et al.Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification[J]. Clin Cancer Res, 2011, 17(10): 3341-3348.
[22] Yoshida A, Shibata T, Tsuta K, et al.Inflammatory myofibroblastic tumour of the lung with a novel PPFIBP1-ALK fusion variant[J]. Histopathology, 2013, 63(6): 881-883.
[23] Wang X, Krishnan C, Nguyen EP, et al.Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor[J]. Hum Pathol, 2012, 43(11): 2047-2052.
[24] Lovly CM, Gupta A, Lipson D, et al.Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions[J]. Cancer Discov, 2014, 4(8): 889-895.
[25] Davies KD, Doebele RC.Molecular pathways: ROS1 fusion proteins in cancer[J]. Clin Cancer Res, 2013, 19(15): 4040-4045.
[26] 段衍超, 郭农建. ETV6-NTRK3 融合基因研究进展[J]. 医学综述, 2008, 14(4): 528-530.
[27] Alassiri AH, Ali RH, Shen Y,et al.ETV6-NTRK3 is expressed in a subset of ALK-Negative inflammatory myofibroblastic tumors[J]. Am J Surg Pathol, 2016, 40(8): 1051-1061.
[28] Pettinato G, Manivel JC, De Rosa N, et al.Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations[J]. Am J Clin Pathol, 1990, 94(5): 538-546.
[29] Pisciotto PT, Gray GF Jr, Miller DR.Abdominal plasma cell pseudotumor[J]. J Pediatr, 1978, 93(4): 628-630.
[30] Ong HS, Ji T, Zhang CP, et al.Head and neck inflammatory myofibroblastic tumor(IMT): evaluation of clinicopathologic and prognostic features[J]. Oral Oncol, 2012, 48(2): 141-148.
[31] 李卉, 王德玲, 刘学文, 等. 头颈部炎性肌纤维母细胞瘤的影像表现及临床特点[J]. 中国肿瘤临床, 2012, 39(24): 2094-2097.
[32] Chan JK, Cheuk W, Shimizu M.Anaplastic lymphoma kinase expression in inflammatory pseudotumors[J]. Am J Surg Pathol, 2001, 25(6): 761-768.
[33] Fisher C, Goldblum JR, Montgomery E.Calponin and h-caldesmon in sarcomas of myofibroblasts[J]. Mod Pathol, 2003, 16(4): 11A.
[34] Cook JR, Dehner LP, Collins MH, et al.Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study[J]. Am J Surg Pathol, 2001, 25(11): 1364-1371.
[35] Ma Z, Hill DA, Collins MH, et al.Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor[J]. Genes Chromosomes Cancer, 2003, 37(1): 98-105.
[36] Hallberg B, Palmer RH.Crizotinib-latest champion in the cancer wars?[J]. N Engl J Med, 2010, 363(18): 1760-1762.
[37] Croegaert K, Kolesar JM.Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer[J]. Am J Health Syst Pharm, 2015, 72(17): 1456-1462.
[38] Minoo P, Wang HY.ALK-immunoreactive neoplasms[J]. Int J Clin Exp Pathol, 2012, 5(5): 397-410.
[39] Gaudichon J, Jeanne-Pasquier C, Deparis M, et al.Complete and repeated response of a metastatic ALK-rearranged inflammatory myofibroblastic tumor to crizotinib in a teenage girl[J]. J Pediatr Hematol Oncol, 2016, 38(4): 308-311.
[40] Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor[J]. N Engl J Med, 2010, 363(18): 1727-1733.
[41] Affara NI, Coussens LM.IKKalpha at the crossroads of inflammation and metastasis[J]. Cell, 2007, 129(1): 25-26.
[42] Gasparini G, Longo R, Sarmiento R, et al.Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?[J]. Lancet Oncol, 2003, 4(10): 605-615.
[43] Smith WL, De Witt DL, Garavito RM.Cyclooxygenases: structural, cellular, and molecular biology[J]. Annu Rev Biochem, 2000, 69: 145-182.
[44] Singh B, Berry JA, Shoher A, et al.COX-2 overexpression increases motility and invasion of breast cancer cells[J]. Int J Oncol, 2005, 26(5): 1393-1399.
[45] Chow LW, Loo WT, Toi M.Current directions for COX-2 inhibition in breast cancer[J]. Biomed Pharmacother, 2005, 59(Suppl 2): S281-284.
[46] Wang G, Li J, Zhang L, et al.Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway[J]. Biochem Biophys Res Commun, 2017, 490(3): 969-976.
[47] Applebaum H, Kieran MW, Cripe TP.The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study[J]. J Pediatr Surg, 2005, 40(6): 999-1003.
[48] Debelenko LV, Arthur DC, Pack SD, et al.Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor[J]. Lab Invest, 2003, 83(9): 1255-1265.